東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Consequences of WDR5 Targeted Degrad...

Siladi, Andrew,

FindBook

Google Book

Amazon

博客來

Consequences of WDR5 Targeted Degradation in Human Cancer Cells /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Consequences of WDR5 Targeted Degradation in Human Cancer Cells // Andrew Siladi.
作者:	Siladi, Andrew,
面頁冊數:	1 electronic resource (204 pages)
附註:	Source: Dissertations Abstracts International, Volume: 85-12, Section: B.
Contained By:	Dissertations Abstracts International85-12B.
標題:	Cellular biology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31342329
ISBN:	9798382609140

Consequences of WDR5 Targeted Degradation in Human Cancer Cells /
Siladi, Andrew,

Consequences of WDR5 Targeted Degradation in Human Cancer Cells /Andrew Siladi. - 1 electronic resource (204 pages)

Source: Dissertations Abstracts International, Volume: 85-12, Section: B.

WDR5 is a highly-conserved nuclear protein which facilitates the assembly of histone-modifying complexes involved in a variety of chromatin-based, gene regulatory processes. WDR5 is best known for its role in scaffolding the assembly of MLL/SET histone methyltransferase complexes that catalyze histone H3 lysine 4 (H3K4) di- and tri-methylation (Me2/Me3), but WDR5 acts outside this setting to promote ribosomal protein gene transcription and recruit the oncogenic transcription factor MYC to chromatin. WDR5 is also a target for pharmacological inhibition in cancer, and most drug discovery efforts aim to block the WIN site of WDR5, an arginine binding cavity that engages MLL/SET enzymes. Therapeutic application of WIN site inhibitors is complicated by the disparate functions of WDR5, but is generally guided by two assumptions-that WIN site inhibitors disable all functions of WDR5, and that changes in H3K4me drive the transcriptional response of cancer cells to WIN site blockade. Here, we test these assumptions by comparing the impact of WIN site inhibition versus WDR5 degradation on H3K4me and transcriptional processes in Burkitt lymphoma and neuroblastoma cell lines. We show that WDR5 regulates transcription widely, yet WIN site inhibition disables only a specific subset of WDR5 activity, and that H3K4me changes induced by WDR5 depletion do not explain accompanying transcriptional responses. Additionally, WDR5 degradation results in the collateral loss of SET1/MLL proteins. These data recast WIN site inhibitors as selective loss-of-function agents, contradict H3K4me as a relevant mechanism of action for WDR5 inhibitors, and point to distinct clinical applications of WIN site inhibitors and WDR5 degraders.

English

ISBN: 9798382609140Subjects--Topical Terms:

3172791
Cellular biology.
Subjects--Index Terms:

Cancer

Consequences of WDR5 Targeted Degradation in Human Cancer Cells /
LDR:03187nmm a22004453i 4500 001 2433907
005 20250909080246.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798382609140
035 $a (MiAaPQD)AAI31342329
035 $a (MiAaPQD)0242vireo2013Siladi
035 $a AAI31342329
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Siladi, Andrew, $e author. $3 3823693
245 1 0 $a Consequences of WDR5 Targeted Degradation in Human Cancer Cells / $c Andrew Siladi.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (204 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-12, Section: B.
500 $a Advisors: Lee, Ethan Committee members: Hodges, Emily; Lau, Ken; Nordman, Jared; Tansey, William P.
502 $b Ph.D. $c Vanderbilt University $d 2024.
520 $a WDR5 is a highly-conserved nuclear protein which facilitates the assembly of histone-modifying complexes involved in a variety of chromatin-based, gene regulatory processes. WDR5 is best known for its role in scaffolding the assembly of MLL/SET histone methyltransferase complexes that catalyze histone H3 lysine 4 (H3K4) di- and tri-methylation (Me2/Me3), but WDR5 acts outside this setting to promote ribosomal protein gene transcription and recruit the oncogenic transcription factor MYC to chromatin. WDR5 is also a target for pharmacological inhibition in cancer, and most drug discovery efforts aim to block the WIN site of WDR5, an arginine binding cavity that engages MLL/SET enzymes. Therapeutic application of WIN site inhibitors is complicated by the disparate functions of WDR5, but is generally guided by two assumptions-that WIN site inhibitors disable all functions of WDR5, and that changes in H3K4me drive the transcriptional response of cancer cells to WIN site blockade. Here, we test these assumptions by comparing the impact of WIN site inhibition versus WDR5 degradation on H3K4me and transcriptional processes in Burkitt lymphoma and neuroblastoma cell lines. We show that WDR5 regulates transcription widely, yet WIN site inhibition disables only a specific subset of WDR5 activity, and that H3K4me changes induced by WDR5 depletion do not explain accompanying transcriptional responses. Additionally, WDR5 degradation results in the collateral loss of SET1/MLL proteins. These data recast WIN site inhibitors as selective loss-of-function agents, contradict H3K4me as a relevant mechanism of action for WDR5 inhibitors, and point to distinct clinical applications of WIN site inhibitors and WDR5 degraders.
546 $a English
590 $a School code: 0242
650 4 $a Cellular biology. $3 3172791
650 4 $a Oncology. $3 751006
650 4 $a Developmental biology. $3 592588
650 4 $a Genetics. $3 530508
653 $a Cancer
653 $a Epigenetics
653 $a Drug discovery
653 $a Pharmacological inhibition
690 $a 0379
690 $a 0992
690 $a 0369
690 $a 0758
710 2 $a Vanderbilt University. $e degree granting institution. $3 3765842
720 1 $a Lee, Ethan $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 85-12B.
790 $a 0242
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31342329